Annexon (ANNX) Stock Analysis

What Annexon does

Annexon, Inc. is a biopharmaceutical company currently engaged in clinical trials, dedicated to the discovery and advancement of therapies for a variety of autoimmune, neurodegenerative, and ophthalmic conditions. Central to its approach is the C1q molecule, which initiates the classical complement pathway. The company targets this pathway to address specific disease mechanisms, such as those seen in antibody-mediated autoimmune disorders and complement-driven neurodegeneration. The company's developmental pipeline features several promising candidates. ANX005, a monoclonal antibody, is in advanced clinical testing, undergoing Phase II/III trials for Guillain-Barré syndrome, as well as Phase II trials for warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis. Another candidate, ANX009, is currently in Phase Ib studies for lupus nephritis. Additionally, ANX007 is progressing through Phase II clinical trials for the treatment of geographic atrophy, an eye disease. Further investigational assets include ANX105, a monoclonal antibody being developed for neurodegenerative indications, and ANX1502, an oral small molecule under investigation for specific autoimmune conditions. Annexon, Inc. was established in 2011 and operates from its headquarters in Brisbane, California.

Key metrics

ETFs linked to ANNX

Broad-market and Healthcare sector ETFs an investor holding Annexon is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ANNX fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Annexon?

Annexon trades under the ticker ANNX on NASDAQ.

Which exchange is ANNX listed on?

ANNX is listed on NASDAQ.

What sector does Annexon operate in?

Annexon is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze ANNX in a portfolio?

PortView shows ANNX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.